ArticleBlood2008
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01520402 (Quantitative Pharmacogenomics of the Anticoagulant Response to Warfarin in Healthy Subjects), which is not on this map. Cited by 208 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Quantitative Pharmacogenomics of the Anticoagulant Response to Warfarin in Healthy Subjects
Who cites it
208 citing papers in PubMed, 9 syntheses or guidelines pooled it, 486 citations in OpenAlex.
- Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.Blood advances · 2024Pooled it
- Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations.Clinical and translational science · 2022Pooled it
- Influence ofCardiovascular therapeutics · 2021Pooled it
- Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials.The pharmacogenomics journal · 2015Pooled it
- Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval.The pharmacogenomics journal · 2014Pooled it
- Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.The pharmacogenomics journal · 2013Pooled it
- Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.Clinical pharmacology and therapeutics · 2012Pooled it
- Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.PloS one · 2012Pooled it
- Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis.Annals of the rheumatic diseases · 2011Pooled it
- A pharmacogenetic versus a clinical algorithm for warfarin dosing.The New England journal of medicine · 2013Trial
- Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses.Clinical medicine & research · 2011Trial
- Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.European journal of clinical pharmacology · 2011Trial
- Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers.Clinical pharmacology and therapeutics · 2010Trial
- Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.Pharmacogenetics and genomics · 2009Trial
- The curious family of cytochrome P450 4F fatty acid ω-hydroxylases: recent developments in their function and relevance for human health.Open biology · 2025Review
- A functional genomic framework to elucidate novel causal non-alcoholic fatty liver disease genes.medRxiv : the preprint server for health sciences · 2024Article
- Pharmacogenomic knowledge and awareness among diverse patients treated with angiotensin converting enzyme inhibitors.Pharmacogenomics · 2023Article
- Novel Gene Polymorphisms for Stable Warfarin Dose in a Korean Population: Genome-Wide Association Study.Biomedicines · 2023Article
- Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP).The pharmacogenomics journal · 2023Article
- Multi-Omics Studies in Historically Excluded Populations: The Road to Equity.Clinical pharmacology and therapeutics · 2023Review
148 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
Warfarin dosing is correlated with polymorphisms in vitamin K epoxide reductase complex 1 (VKORC1) and the cytochrome P450 2C9 (CYP2C9) genes. Recently, the FDA revised warfarin labeling to raise physician awareness about these genetic effects. Randomized clinical trials are underway to test genetically based dosing algorithms. It is thus important to determine whether common single nucleotide polymorphisms (SNPs) in other gene(s) have a large effect on warfarin dosing. A retrospective genome-wide association study was designed to identify polymorphisms that could explain a large fraction of the dose variance. White patients from an index warfarin population (n = 181) and 2 independent replication patient populations (n = 374) were studied. From the approximately 550 000 polymorphisms tested, the most significant independent effect was associated with VKORC1 polymorphisms (P = 6.2 x 10(-13)) in the index patients. CYP2C9 (rs1057910 CYP2C9*3) and rs4917639) was associated with dose at moderate significance levels (P approximately 10(-4)). Replication polymorphisms (355 SNPs) from the index study did not show any significant effects in the replication patient sets. We conclude that common SNPs with large effects on warfarin dose are unlikely to be discovered outside of the CYP2C9 and VKORC1 genes. Randomized clinical trials that account for these 2 genes should therefore produce results that are definitive and broadly applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.